In 2019, a woman in Nashville named Victoria Gray became the first patient treated with CRISPR gene-editing technology for sickle-cell disease, a condition that had defined her life through recurring, debilitating pain crises since childhood. Years on, she remains free of the crises that once sent her to hospital every few weeks. What was once managed, sometimes barely, is now something closer to being resolved. Sickle-cell disease has joined a small but growing list of conditions, alongside cystic fibrosis since the arrival of Trikafta and metabolic illness reshaped by GLP-1 receptor agonists, where medicine has moved from management to something approaching cure.
None of this is free, and Britain has spent the past year working out, in concrete policy terms, what it is willing to pay for it.
The mechanism is unglamorous but consequential. The Voluntary Scheme for Branded Medicines Pricing, Access and Growth, known as VPAG, caps how fast NHS spending on branded medicines can grow and requires pharmaceutical companies to rebate the government when sales exceed that cap. Through 2025 the rebate rate reached 22.9 per cent, a level the industry regarded as punitive enough that some firms began talking openly about withdrawing products or shelving UK investment. Talks to soften the terms collapsed acrimoniously that summer. Only as part of a wider trade settlement with Washington did the government agree, at the end of last year, to cut the 2026 rebate to 14.5 per cent and hold it at no more than 15 per cent through 2028. NICE's cost-effectiveness thresholds, the bar a new treatment must clear to be judged worth NHS funding, were raised alongside it, and ministers committed to lifting medicines spending from 0.3 to 0.6 per cent of GDP over the coming decade.
This is the practical answer to the dilemma that cell and gene therapies pose everywhere: a treatment that cures rather than manages a lifelong condition can carry a price tag in the hundreds of thousands of pounds, reflecting years of R&D risk that the manufacturer needs to recoup, and a health system with a fixed budget has to decide whether that arithmetic is one it can live with. The UK's answer, for now, is to buy relative goodwill with industry through a lower clawback, wagering that the alternative, continued flight of investment and product launches, would cost the NHS pipeline more than the rebate ever recovered.
It is a bet rather than a resolution. The Association of the British Pharmaceutical Industry welcomed the greater certainty the new cap provides but was explicit that UK payment rates remain higher than in comparable European markets, and that the NHS still needs to move faster in adopting the medicines it has agreed to pay for. That second point matters as much as the rate itself. A rebate concession achieves little for patients if NICE approval and NHS adoption pathways remain slow enough that gene therapies reach only a handful of specialist centres years after licensing. The gap between a treatment being approved and a treatment being routinely available is where most of the real access problem sits, and no amount of rebate engineering closes it on its own.
There is also the question of durability. The 2025 negotiations broke down once already, and the current settlement was reached only as a side effect of a bilateral trade deal rather than a domestically negotiated consensus between government and industry. Whether that arrangement survives the pressures of the coming financial year, including whatever the October Budget delivers for departmental spending, is genuinely open. A government that needs savings will always eye a rebate scheme paying dividends to the Treasury with some interest.
What the Gray case demonstrates, and what British policymakers now have to live with, is that the golden age of medicine does not arrive evenly. It arrives as a bill, and someone has to decide, treatment by treatment, budget cycle by budget cycle, whether the country can afford to say yes.
